Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Healthtrust
Federal Trade Commission
Teva
Argus Health
Fish and Richardson
Johnson and Johnson
Baxter
McKinsey
Moodys

Generated: August 20, 2017

DrugPatentWatch Database Preview

RENORMAX Drug Profile

« Back to Dashboard

What is the patent landscape for Renormax, and when can generic versions of Renormax launch?

Renormax is a drug marketed by Schering and is included in one NDA.

The generic ingredient in RENORMAX is spirapril hydrochloride. Additional details are available on the spirapril hydrochloride profile page.

Summary for Tradename: RENORMAX

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list20
Patent Applications: see list2,344
Drug Prices:see details
DailyMed Link:RENORMAX at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-001Dec 29, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-004Dec 29, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-002Dec 29, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-003Dec 29, 1994DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RENORMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-001Dec 29, 1994► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-003Dec 29, 1994► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-002Dec 29, 1994► Subscribe► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-004Dec 29, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Julphar
Express Scripts
Cipla
Cerilliant
Harvard Business School
QuintilesIMS
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot